Skip to main content
. 2023 Nov 11;14:7301. doi: 10.1038/s41467-023-42900-4

Fig. 3. Kaplan–Meier PFS and OS curves of dostarlimab plus chemotherapy and pembrolizumab plus chemotherapy.

Fig. 3

a PFS (data cut-off: August 4, 2022) and b OS (data cut-off: July 7, 2023) Note: + symbols represent individual censoring events. CI confidence interval, HR hazard ratio, NR not reached, OS overall survival, PFS progression-free survival.